Top Healthcare Stocks by UQS Score

1152 stocks scored · Last updated August 23, 2026

Healthcare is one of the few sectors where demand is structurally guaranteed — aging populations, chronic disease prevalence, and innovation-driven treatment cycles create persistent tailwinds regardless of economic conditions. But the sector spans an enormous range: from cash-burning biotech startups hoping for FDA approval to diversified pharma giants with decades of patent-protected revenue. The UQS model cuts through this noise by scoring actual financial performance and balance sheet health, not pipeline potential. Companies ranked highest here have already demonstrated they can turn scientific innovation into profitable, sustainable businesses.

Healthcare Sector Characteristics

Healthcare encompasses pharmaceuticals, biotechnology, medical devices, managed care, hospital systems, and life science tools. What makes the sector unique for scoring is its bimodal distribution: large pharma companies tend to have exceptional quality scores (high margins from patented drugs) but modest growth scores (patent cliffs create revenue headwinds), while smaller biotech companies show the inverse pattern. Medical device companies often hit a sweet spot — consistent revenue growth with defensible market positions and recurring consumable revenue. The UQS model captures these dynamics by scoring each metric independently, so a pharma company isn't penalized for slow growth if it excels everywhere else.

Scoring note: Healthcare uses consumer-sector thresholds (25% ROIC, 30% operating margin) because pharmaceutical margins vary widely depending on patent cliffs and R&D spending cycles. Biotech companies with negative earnings can still score well on growth and moat if they have strong pipelines and low debt.

Healthcare Sector Score Overview

67

Avg UQS Score

82

Avg Quality

42

Avg Moat

64

Avg Growth

83

Avg Risk

74

Avg Valuation

Top Healthcare Stocks: Who Leads and Why

#1HRMYHarmony Biosciences Holdings, Inc.76

Harmony Biosciences Holdings, Inc. leads healthcare with a 76 UQS score, driven by a 78 quality rating that reflects superior margins and capital returns. Its moat score of 43 confirms deep competitive advantages in its therapeutic areas.

#2ARGXargenx SE74

argenx SE scores 74 overall, balancing strong profitability (quality: 80) with a robust balance sheet (risk: 100). A well-diversified revenue base supports scoring consistency.

#3INCYIncyte Corporation72

At 72, Incyte Corporation earns the third spot with notable strength in valuation (74) — suggesting the market may be underpricing its fundamentals relative to the quality of the business.

#4GLPG.ASLakefront Biotherapeutics71

Lakefront Biotherapeutics scores 71 with balanced pillar scores, indicating a well-rounded healthcare business with no major scoring weaknesses.

#5ALNYAlnylam Pharmaceuticals, Inc.70

Alnylam Pharmaceuticals, Inc. scores 70 with balanced pillar scores, indicating a well-rounded healthcare business with no major scoring weaknesses.

Full Healthcare Ranking: Top 25 Stocks

#	Stock	UQS	Q	M	G	R	V
1	HRMYHarmony Biosciences Holdings, Inc.	76	78	43	79	98	98
2	ARGXargenx SE	74	80	55	100	100	38
3	INCYIncyte Corporation	72	100	44	48	100	74
4	GLPG.ASLakefront Biotherapeutics	71	65	50	61	100	99
5	ALNYAlnylam Pharmaceuticals, Inc.	70	78	53	100	76	40
6	NUTXNutex Health, Inc.	70	93	32	69	76	100
7	CGENCompugen Ltd.	70	100	25	63	82	98
8	VRTXVertex Pharmaceuticals Incorporated	70	84	55	64	100	49
9	CELG-RIBristol-Myers Squibb Company Ce	69	92	48	74	28	100
10	DXCMDexCom, Inc.	69	86	50	76	77	52
11	CRMDCorMedix Inc.	68	97	46	53	100	47
12	NBIXNeurocrine Biosciences, Inc.	66	80	38	90	61	65
13	CPH.TOCipher Pharmaceuticals Inc.	66	86	30	70	84	71
14	SPROSpero Therapeutics, Inc.	66	96	15	54	82	100
15	GILDGilead Sciences, Inc.	66	92	51	47	60	77
16	REGNRegeneron Pharmaceuticals, Inc.	65	70	46	46	100	80
17	GMEDGlobus Medical, Inc.	65	68	36	75	82	79
18	SLNOSoleno Therapeutics, Inc.	65	81	35	61	100	57
19	QTTBQ32 Bio Inc.	65	83	28	38	100	96
20	NVONovo Nordisk A/S	64	88	61	20	60	95
21	BMRNBioMarin Pharmaceutical Inc.	64	48	51	65	100	77
22	ELMDElectromed, Inc.	64	73	39	82	82	50
23	PLXProtalix BioTherapeutics, Inc.	64	89	27	51	97	66
24	IDXXIDEXX Laboratories, Inc.	63	88	60	56	64	35
25	CCLDCareCloud, Inc.	63	66	35	58	75	100

Filter all 1152+ healthcare stocks in the full directory

Browse All Stocks

Frequently Asked Questions About Healthcare Stocks

How does UQS handle biotech companies with no revenue?

Pre-revenue biotech companies typically score low overall because most UQS metrics require financial data (revenue, margins, earnings). Their quality score will be near zero, and growth metrics that depend on trailing revenue won't have data. However, if a biotech has low debt and strong cash reserves, it can score reasonably on risk. The moat score, being AI-driven, can also recognize strong IP portfolios and regulatory moats even for pre-revenue companies.

Why do healthcare stocks often score high on quality?

Pharmaceutical companies with patent-protected drugs enjoy some of the highest margins in the market — gross margins of 70-80% are common. Patents create temporary monopolies that allow premium pricing, and the regulatory approval process creates enormous barriers to entry. These structural advantages directly translate into high ROIC, wide operating margins, and strong free cash flow generation — exactly what the quality pillar measures.

What impact do patent cliffs have on UQS scores?

Patent expiration directly affects growth scores as revenue from blockbuster drugs declines. Quality scores may also dip as margins compress from generic competition. However, well-managed pharma companies with diversified pipelines often maintain their overall UQS scores by replacing expiring revenue with new drug launches. The three-year revenue CAGR in the growth pillar helps distinguish between transient patent cliff effects and structural decline.